PD32 Cost-Utility Of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres For Chemotherapy-Refractory Metastatic Colorectal Cancer In Brazil

Introduction There were an estimated 55,102 new cases of colorectal cancer (CRC) in Brazil 2020, comprising 9.3 percent all newly diagnosed cancers, and making it the third most common Brazilian population. Up to half patients with CRC will develop liver metastases, prognosis for these is poor. The objective present analysis was evaluate cost-utility selective internal radiation therapy (SIRT) using Y-90 resin microspheres versus best supportive care (BSC) unresectable, liver-dominant, chemotherapy-refractory metastatic (mCRC). Methods A three-state partitioned survival model developed Microsoft Excel SIRT BSC. Membership three states pre-progression, post-progression death governed by parametric models Kaplan-Meier data from a retrospective, interventional study. Costs associated microspheres, BSC, adverse events obtained sources reported 2021 United States dollars (USD). Future costs effects discounted at 5 percent. One-way probabilistic sensitivity analyses (PSA) performed. willingness-to-pay threshold USD 53,936 used based on 2017 review healthcare technology adoption. Results base case showed that would result increase 0.76 QALYs increasing quality-adjusted life expectancy 0.67 1.43 QALYs. improvement accompanied 9,884 40,399 over time horizon, corresponding 30,515, yielding incremental ratio (ICUR) 40,265 per QALY gained. PSA there 90.8 likelihood cost-effectiveness Conclusions cost-effective BSC treatment liver-dominant mCRC should be considered incorporation Private Healthcare System.